Evaluation of GenoType MTBDRplus for the Detection of Drug-resistant Mycobacterium Tuberculosis on Isolates from Karachi, Pakistan

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Aug 20

PMID 31425565

Citations 8

Authors

Sara Siddiqui

Meredith B Brooks

Amyn A Malik

Junaid Fuad

Ahsana Nazish

Safia Bano

Mercedes C Becerra

Hamidah Hussain

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the diagnostic performance of the GenoType MRBDRplus assay with the gold standard phenotypic drug susceptibility testing in the detection of drug resistance among culture isolates obtained from patients in Karachi, Pakistan.

Design: Mycobacterium tuberculosis isolates were obtained from 96 consecutive tuberculosis patients found to have resistance to isoniazid from two health centers in Karachi (January-November 2017). Isolates were tested for drug resistance against rifampin and isoniazid using the MTBDRplus assay. Results were compared with conventional drug-susceptibility testing and the frequency of specific mutations were reported.

Results: The MTBDRplus assay had a sensitivity for rifampin resistance of 98.8% (95% CI: 93.4-100) and for isoniazid resistance of 90.6% (95% CI: 83.0-95.6). The MTBDRplus assay showed mutations in rpoB in 81 of the 96 (84.4%) isolates. Of the 87 isolates showing resistance to isoniazid via the MTBDRplus assay, 71 (74.0%) isolates had mutations in the katG gene only, 15 (15.6%) isolates had mutations in the inhA promoter region, and 1 (1.0%) showed mutations in both genes.

Conclusion: The GenoType MTBDRplus assay in Pakistan can identify subgroups at high-risk of having isolates with mutations in the katG and/or inhA genes. Understanding the local burden of these mutations have implications for local diagnostic and treatment guidelines.

Citing Articles

Surveillance of fluoroquinolones resistance in rifampicin-susceptible tuberculosis in eastern China with whole-genome sequencing-based approach.

Che Y, Lu Y, Zhu Y, He T, Li X, Gao J Front Microbiol. 2024; 15:1413618.

PMID: 39050625 PMC: 11266052. DOI: 10.3389/fmicb.2024.1413618.

Evaluating the Sensitivity of Different Molecular Techniques for Detecting Complex in Patients with Pulmonary Infection.

Hemeg H, Albulushi H, Ozbak H, Ali H, Alahmadi E, Almutawif Y Pol J Microbiol. 2023; 72(4):421-431.

PMID: 37934050 PMC: 10725165. DOI: 10.33073/pjm-2023-040.

Molecular characterization of genetic mutations with fitness loss in pulmonary tuberculosis patients associated with HIV co-infection in Northwest Amhara, Ethiopia.

Seid A, Kassa M, Girma Y, Dereb E, Nureddin S, Abebe A SAGE Open Med. 2023; 11:20503121231208266.

PMID: 37933292 PMC: 10625730. DOI: 10.1177/20503121231208266.

Evaluation of whole-genome sequence to predict drug resistance of nine anti- drugs and characterize resistance genes in clinical rifampicin-resistant isolates from Ningbo, China.

Che Y, Lin Y, Yang T, Chen T, Sang G, Chen Q Front Public Health. 2022; 10:956171.

PMID: 36062095 PMC: 9433565. DOI: 10.3389/fpubh.2022.956171.

Drug Resistance Conferring Mutation and Genetic Diversity of Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia.

Ayalew S, Wegayehu T, Taye H, Wassie L, Girma S, Berg S Infect Drug Resist. 2021; 14:575-584.

PMID: 33623398 PMC: 7894881. DOI: 10.2147/IDR.S298683.

References

Piersimoni C, Olivieri A, Benacchio L, Scarparo C . Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J Clin Microbiol. 2006; 44(1):20-8. PMC: 1351976. DOI: 10.1128/JCM.44.1.20-28.2006. View

Cavusoglu C, Turhan A, Akinci P, Soyler I . Evaluation of the Genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates. J Clin Microbiol. 2006; 44(7):2338-42. PMC: 1489470. DOI: 10.1128/JCM.00425-06. View

Schaaf H, Victor T, Engelke E, Brittle W, Marais B, Hesseling A . Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur J Clin Microbiol Infect Dis. 2007; 26(3):203-5. DOI: 10.1007/s10096-007-0257-9. View

Hillemann D, Rusch-Gerdes S, Richter E . Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2007; 45(8):2635-40. PMC: 1951233. DOI: 10.1128/JCM.00521-07. View

Vilcheze C, Jacobs Jr W . The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol. 2007; 61:35-50. DOI: 10.1146/annurev.micro.61.111606.122346. View

Katiyar S, Bihari S, Prakash S, Mamtani M, Kulkarni H . A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2008; 12(2):139-45. View

Bwanga F, Hoffner S, Haile M, Joloba M . Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis. 2009; 9:67. PMC: 2696456. DOI: 10.1186/1471-2334-9-67. View

Ali A, Hasan R, Jabeen K, Jabeen N, Qadeer E, Hasan Z . Characterization of mutations conferring extensive drug resistance to Mycobacterium tuberculosis isolates in Pakistan. Antimicrob Agents Chemother. 2011; 55(12):5654-9. PMC: 3232797. DOI: 10.1128/AAC.05101-11. View

Vadwai V, Ajbani K, Jose M, Vineeth V, Nikam C, Deshmukh M . Can inhA mutation predict ethionamide resistance?. Int J Tuberc Lung Dis. 2012; 17(1):129-30. DOI: 10.5588/ijtld.12.0511. View

10.

Gupta A, Prakash P, Singh S, Anupurba S . Rapid genotypic detection of rpoB and katG gene mutations in Mycobacterium tuberculosis clinical isolates from Northern India as determined by MAS-PCR. J Clin Lab Anal. 2013; 27(1):31-7. PMC: 6807317. DOI: 10.1002/jcla.21558. View

11.

Machado D, Perdigao J, Ramos J, Couto I, Portugal I, Ritter C . High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. J Antimicrob Chemother. 2013; 68(8):1728-32. DOI: 10.1093/jac/dkt090. View

12.

Madhuri K, Deshpande S, Dharmashale S, Bharadwaj R . Utility of Line Probe Assay for the Early Detection of Multidrug-Resistant Pulmonary Tuberculosis. J Glob Infect Dis. 2015; 7(2):60-5. PMC: 4448326. DOI: 10.4103/0974-777X.157237. View

13.

Bollela V, Namburete E, Feliciano C, Macheque D, Harrison L, Caminero J . Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016; 20(8):1099-104. PMC: 5310937. DOI: 10.5588/ijtld.15.0864. View

14.

Unissa A, Subbian S, Hanna L, Selvakumar N . Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect Genet Evol. 2016; 45:474-492. DOI: 10.1016/j.meegid.2016.09.004. View

15.

Javed H, Bakula Z, Plen M, Hashmi H, Tahir Z, Jamil N . Evaluation of Genotype MTBDR and MTBDR Assays for Rapid Detection of Drug Resistance in Extensively Drug-Resistant Isolates in Pakistan. Front Microbiol. 2018; 9:2265. PMC: 6169422. DOI: 10.3389/fmicb.2018.02265. View

16.

Telenti A, Honore N, Bernasconi C, March J, Ortega A, Heym B . Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol. 1997; 35(3):719-23. PMC: 229657. DOI: 10.1128/jcm.35.3.719-723.1997. View